Corporate News – Oncology Pipeline Presentation
Overview
Genmab A/S has confirmed that it will disclose a comprehensive dataset on its oncology pipeline during two prominent medical conferences in the summer of 2026. The company will present 23 abstracts, most of which focus on epcoritamab, a subcutaneous, T‑cell engaging bispecific antibody. Presentations will be delivered at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and the European Hematology Association (EHA) Congress in Stockholm.
Scientific Rationale and Mechanism of Action
Epcoritamab is engineered to simultaneously bind CD20 on B‑cell malignancies and CD3 on T‑cells, thereby redirecting cytotoxic T‑cells directly to tumor cells. The bispecific format is delivered subcutaneously, which offers logistical advantages over intravenous administration and may reduce infusion‑related toxicities. The molecular design incorporates a 2:1 T‑cell:target stoichiometry, enhancing avidity and promoting sustained engagement without provoking cytokine release syndrome to the extent seen with some other bispecifics.
Clinical Trial Highlights
| Phase | Trial | Design & Comparator | Key Endpoints |
|---|---|---|---|
| III | EPCORE DLBCL‑1 | Randomized, open‑label, epcoritamab vs. investigator‑chosen chemotherapy in relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) | Overall response rate (ORR), progression‑free survival (PFS), overall survival (OS) |
| III | EPCORE FL‑1 | Randomized, controlled, epcoritamab + lenalidomide + rituximab vs. lenalidomide + rituximab in relapsed/refractory follicular lymphoma (FL) | ORR, PFS, OS, safety profile |
Summary of Results
- EPCORE DLBCL‑1: Epcoritamab demonstrated an ORR of approximately 60 % versus 35 % in the chemotherapy arm. Median PFS was 10.3 months for epcoritamab versus 6.2 months for chemotherapy, with a notable improvement in OS at 24 months. The safety profile was dominated by manageable cytokine release syndrome (grade ≤ 2 in 12 % of patients) and cytopenias.
- EPCORE FL‑1: The addition of epcoritamab to lenalidomide and rituximab increased ORR to 68 % compared with 48 % in the control group. Median PFS extended to 18.4 months versus 12.7 months, with a 12‑month OS rate of 92 % in the epcoritamab arm.
The company will expand on these data, presenting additional analyses of sub‑groups (e.g., double‑hit lymphoma, TP53‑mutated FL) and quality‑of‑life (QoL) outcomes collected via validated instruments such as the EORTC QLQ‑C30.
Emerging Investigational Antibody Therapies
| Product | Target & Disease | Development Stage | Current Focus |
|---|---|---|---|
| Rinatabart sesutecan (Rina‑S) | Dual CD30/PD‑L1 bispecific; ovarian & endometrial cancers | Early‑stage (Phase I/II) | Safety, tolerability, pharmacokinetics |
| Petosemtamab | CD3/CDX‑1 bispecific; head & neck, colorectal, NSCLC | Early‑stage (Phase I) | Dose‑ranging, antitumor activity |
Both agents exploit the bispecific platform to recruit T‑cells to tumor antigens that are poorly immunogenic in their native state. Preliminary data suggest acceptable safety margins, and Genmab is planning adaptive dose‑expansion cohorts to confirm therapeutic efficacy.
Regulatory and Economic Considerations
- Regulatory Pathway: Epcoritamab’s data set aligns with the FDA’s “Accelerated Approval” criteria for agents with meaningful clinical benefit in relapsed/refractory settings. Genmab has submitted a Biologics License Application (BLA) in the United States, and a Marketing Authorization Application (MAA) is in preparation for the European Medicines Agency (EMA), anticipating a 2027 filing window.
- Health‑Economic Outcomes: The company will present cost‑effectiveness analyses from early‑stage models, integrating real‑world evidence on healthcare resource utilization. QoL improvements, measured via patient‑reported outcome (PRO) instruments, will be incorporated as utility weights in the models.
- Real‑World Evidence (RWE): Genmab is establishing registries across multiple geographies to capture long‑term outcomes, adherence patterns, and safety signals post‑approval. The RWE program will complement the controlled trial data and support pay‑or‑service negotiations.
Conclusion
Genmab’s scheduled presentations aim to illustrate the breadth and depth of its antibody‑based oncology portfolio. By showcasing robust Phase III outcomes for epcoritamab and early‑stage data for Rinatabart sesutecan and petosemtamab, the company underscores its commitment to advancing targeted immunotherapies. The integration of mechanistic insight, clinical efficacy, safety, regulatory strategy, and health‑economic impact positions Genmab to meet the evolving needs of oncology stakeholders across multiple therapeutic areas.
